

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

## **VOLUNTARY ANNOUNCEMENT**

### **THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA**

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the U.S. Food and Drug Administration (the "**U.S. FDA**") has approved the Investigational New Drug (IND) application for "CSPCHA115" (the "**Product**"), a new drug developed by the Group for the treatment of allergic rhinitis and asthma.

Pathophysiological studies have shown that some interleukins (IL) such as IL-4, IL-5 and IL-13 are important in the manifestation of allergic rhinitis and asthma, which can be completely blocked by selective prostaglandin D2 (PD2) receptor antagonists. Thus, as a highly selective and potent antagonist for PD2 receptor,"CSPCHA115" might be beneficial for the treatment of allergic rhinitis and asthma.

Non-clinical animal efficacy models in mice and guinea pigs have demonstrated that the Product effectively alleviated allergic rhinitis and asthma. The completed animal safety and toxicology studies did not reveal any major or unexpected safety findings, and the overall safety profile observed in animal studies for the Product appears favorable. Thus, it is reasonable to believe that the Product is safe for human study.

The IND approval obtained from the U.S. FDA will allow the Group to start clinical trials of the Product in the United States (the "**U.S.**"). The Product has also been approved to conduct clinical trials in China. Thus, the Group is now pushing forward with the clinical development of the Product in both the U.S. and China.

“CSPCHA115” is developed by the Group with independent intellectual property rights. Multiple patent applications have been filed in various countries including the U.S. and China.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 10 July 2018

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei, Mr. ZHANG Cuilong and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*